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summary
Introduction. the tumour and treatments have effects on metabolism, nutrition and thus the nutritional status. 
Aim. to reveal nutritional difficulties leading to malnutrition, sarcopenia and to explore possibilities of dietetic intervention. 
to survey patients’ nutritional status and malnutrition risk. Moreover, to assess patients’ energy and nutrient intake and their 
nutrition habits regarding quantity and quality. the question of clinical nutrition was also raised.
Material and methods. inpatients (64.33 years ± 18.62, 22 males/23 females) and outpatients (63.38 ± 16.08, 9 males/15 females) 
were involved, since patients should be provided with different dietetic services in these areas. Malnutrition risk screening was 
performed with nrs 2002. nutritional status was determined based on measured anthropometric parameters and body com-
position analysis. Diet changes were measured by 3-day food diaries and 24-hour food recalls. 
Results. all inpatients are at risk of malnutrition (60% moderately 12% severely). the decrease in muscle mass can be esti-
mated based on calculated values. 16% of the outpatients are at risk of mild malnutrition and 8% had anorexia. 72% of the out-
patients are overweight-obese, however, beside fat dominance, loss of muscle mass is also likely in 80%. inpatients consumed 
1,800 kcal, including supplementary feeding. 22% received supplementary formulas, still only 50-75% of the recommended 
amount is consumed. 41% of severe risk patients do not get ons at all. 
Conclusions. the nutritional status of cancer patients should be examined thoroughly. the provision of supplement formulas, 
tube or parenteral nutrition should be started timely.
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INTRoDUcTIoN
cancer is now recognised as a chronic disease since 
the number of patients living with cancer is increasing. 
Developed treatments enhance survival rates signifi-
cantly and also prolong lifetime (1).
Nutrition of cancer patients is vital from the diagno-
sis onwards. The risk of nutritional depletion is high for 
the following reasons. Due to the metabolic changes 
the tumour triggers, muscle wasting and weigh loss 
occur in patients (2). Symptoms and side effects, such 
as pain, stomach discomfort, diarrhoea, nausea, vom-
iting etc. patients usually suffer from, especially dur-
ing treatment, might impair food intake, not to mention 
they may cause nutrient losses and may prevent nutri-
ent absorption. The psychological effects, most often 
depression and anorexia, have a negative effect on ap-
petite, consequently the energy and nutrient intake is 
much less than the desired amount. For all the above 
mentioned factors, the risk of weight loss and malnu-
trition is high. Approximately 40% of cancer patients 
have been found to have substantial protein energy 
malnutrition (3).
The role of malnutrition which increases morbidity and 
mortality in aging, as well as in patients with chronic dis-
eases such as cancer, has been long recognized (4, 5). 
It is “a state resulting from the lack of uptake or intake 
of nutrition leading to altered body composition (de-
creased fat free mass) and body cell mass leading to 
diminished physical and mental function and impaired 
clinical outcome from disease” (6). 
Furthermore, sarcopenia is a key feature of disease-
related malnutrition. currently the proposed criteria for 
sarcopenia assessment in a clinical setting include the 
determination of muscle mass, strength and physical 
performance (7). It is a syndrome characterised by pro-
gressive and generalised loss of skeletal muscle mass 
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BW in kg, Ht in m, sex = 1 for male and 0 for female, 
race = 1.2 for Asian, 1.4 for African American, and 0 for 
white or Hispanic (13).
cut-off points depend on the chosen measurement 
technique and on the availability of reference studies 
as well. The EWGSoP recommends the use of norma-
tive (healthy young adults) rather than other predictive 
reference populations. The selection of measurement 
tools for research studies relies on availability and ac-
cess to data for relevant reference populations (consid-
ering age, gender and ethnicity). cut-off points can be 
used in case of skeletal muscle mass (SMM) and skel-
etal muscle mass index (SMI) (8). 
According to ESPEN diagnostic measures are only 
needed for those patients who score positive for nutri-
tional risk. In order to diagnose malnutrition there are 
two alternative ways:
 – alternative 1: BMI < 18.5 kg/m2,
 – alternative 2: weight loss (unintentional) > 10% in-
definite of time, or > 5% over the last 3 months com-
bined with either BMI < 20 kg/m2 if < 70 years of age, 
or < 22 kg/m2 if ≥ 70 years of age or FFMI < 15 and 
< 17 kg/m2 in women and men respectively (14). 
Malnutrition risk screening was performed with the 
help of NRS 2002. The changes in diet were measured 
by validated 3-day food diaries and 24-hour food recalls. 
The energy and nutrient intake was compared to recom-
mended necessities.
RESUlTS
It is recommended by ESPEN that subjects at risk 
of malnutrition should be identified by validated screen-
ing tools, moreover should be assessed and treated ac-
cordingly. Based on the NRS 2002 scores all the clinical 
patients proved to be at risk of malnutrition: 28% mildly, 
60% moderately and 12% severely. In case of the first two 
risk categories it is desired to rescreen patients weekly 
but if e.g. a major operation is scheduled, a preventive 
nutritional care plan is considered to avoid the associ-
ated risk status. However, if the Score is ≥ 3, a nutritional 
care plan is indicated and it should be initiated as early 
as possible. Regarding outpatients and their NRS 2002 
Score, 16% was at risk of mild malnutrition.
As it is represented in table 1 19% of the clinical 
patients had low, 51% had normal, 18% had high and 
12% had very high BMI. Among the outpatients 17% 
had low, 12% had normal, 46% had high and 25% had 
very high BMI.
The results of the BIA allowed us to distinguish be-
tween FFMI and FFM. FFMI data for men and women, 
respectively, were categorized as ‘low’ (< 17 kg/m2 and 
< 15 kg/m2). low FFMI was found in16 (73%) male clini-
cal and 6 (67%) male outpatients. 
cut-off values for FFMI were based on Swiss refer-
ence material, recommended by ESPEN. The latter 
offers a more precise description of the investigated 
and strength with a risk of adverse outcomes such as 
physical disability, poor quality of life and death. Di-
agnosis is based on the documentation of low muscle 
mass, low muscle strength and low physical perfor-
mance (8). 
Another factor is cachexia which is widely recogn-
ised in older adults as severe muscle wasting accom-
panying chronic diseases, such as cancer. cachexia 
has recently been defined as a complex metabolic syn-
drome, associated with underlying illnesses and char-
acterised by loss of muscle with or without the loss of 
fat mass (9, 10). 
AIM
our objectives were to reveal the nutritional dif-
ficulties of cancer patients leading to malnutrition and 
sarcopenia; and to explore the possibilities of dietetic 
interventions focusing on nutritional status, body com-
position assessment and malnutrition risk screening. 
Moreover, we wanted to prove that the results of vali-
dated risk screening methods should be complemented 
with complex nutritional status assessment and body 
composition analysis in order to explore muscle loss 
which plays an important role in cancer cachexia. We 
raised the question as to which patient is given clinical 
nutrition, such as formula-fed supplements (oNS), tube 
or parenteral feeding.
MATERIAl AND METHoDS
The study was performed on 45 inpatients (23 fe-
males, 22 males) and 24 outpatients (15 females and 
9 males) aged 64.33 years ± 18.62 and 63.38 ± 16.08 
respectively.
A wide range of techniques can be used to assess 
body composition and malnutrition (11). However, 
we have selected the measuring methods which are 
also applied by dietitians in their daily clinical prac-
tice. First of all, body composition was measured by 
a 4-point oMRoN BF 500 Bioimpedance analysis (BIA) 
device. Secondly, body weight was recorded in light 
clothing, standing barefoot on the machine. Thirdly, 
body height was measured separately, with the help of 
a wall-mounted stadiometer. The test itself is inexpen-
sive, easy to use, readily reproducible and appropriate 
for both ambulatory and bedridden patients, although 
some clinical studies assume that BIA cannot reliably 
assess skeletal muscle mass in patients with body fluid 
abnormalities (12).
The estimation of skeletal muscle mass (SMM) was 
calculated with the equation of lee et al. (body weight 
and height model). This equation was cross-validated 
with the independent samples of obese subjects. Pre-
diction equations have been validated for multi-ethnic 
adults. The lee et al. equation is the following:
SM (kg) = (0.244 x BW) + (7.80 x Ht) – (0.098 x age) 
+ (6.6 x sex) + (race - 3.3)
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patients than BMI, thus providing a better justification 
for nutritional care plans. Although calculating patients’ 
FFMI for the diagnosis of malnutrition is not part of the 
daily routine care, hopefully the need to provide acces-
sible techniques to analyse body composition in various 
health care settings will be advocated.
The prevalence of sarcopenia was ascertained, 
based on the skeletal muscle index (SMI). EWSGoP 
cut-off points were used in order to analyse and com-
pare the SMI values. It is outstanding that even patients 
with normal or high BMI show reduced muscle mass 
according to bioelectrical impedance analysis (BIA). 
Among the inpatients 55% (15 males and 9 females) 
suffer from moderate, whereas 14% suffer from severe 
sarcopenia. Understandably, this percentage is lower 
in case of the outpatients; however, it is still noteworthy 
that almost 30% (6 males and 1 female) is exposed to 
moderate sarcopenia. These numbers do not correlate 
with the BMI categories, since according to them 18% of 
the clinical and 16% of the outpatients can be consid-
ered as sarcopenic. In patients with muscle wasting the 
energy requirement is usually overestimated, resulting 
in fat deposition which may therefore lead to sarcope-
nic obesity. This phenomenon means significant muscle 
loss with relative fat abundance even when BMI is nor-
mal or high (7).
The daily energy expenditure at rest and during 
physical activity is primarily determined by skeletal mus-
cle mass. Hence, in case of muscle disuse atrophy the 
energy requirement is decreased. If it is not taken into 
consideration, the rate of fat deposition will increase en-
hancing systematic inflammation and insulin resistance, 
thus the vicious circle of progressive muscle loss and 
fat gain, which is frequently observed in patients with 
cancer (7).
Patients’ energy and nutrient intake is demonstrated 
in table 2. Regarding inpatients the average daily intake, 
including the oral nutritional support, is around 1800 kcal. 
Due to the metabolical changes the aim is not to overfeed 
the patients, as it accelerates muscle loss and activates 
systematic inflammation in bedridden subjects. However, 
the 1-1.1 g protein/kg body weight intake should be in-
creased to 1.2-1.5 g/kg body weight/day to counteract 
the anabolic resistance. For muscle-depleted patients 
with increased fat mass both endurance and resistance-
type exercises would be recommended to maintain skel-
etal muscle mass and functions (7).
In terms of the outpatients, the average 2770 kcal en-
ergy intake per day exceeds the recommendations. Not 
to mention the fact that the extreme consumption of fat 
is at the expense of carbohydrates and protein. Dietetic 
intervention should focus on meal planning and the edu-
cation of cancer patients.
Focusing on oral nutrition support, it has been re-
vealed that 22% of the clinical patients (10 subjects) 
received 2-3 bottles/day of drinking formulas. Two of 
Table 1. characteristics of the patients included in the 
study.
Data
Inpatients 
(n = 45)
n; mean ± SD
Outpatients 
(n = 24)
n; mean ± SD
Gender
Men (n) 22 9
Women (n) 23 15
Age (years) 64.33 ± 18.62 63.38 ± 16.08
Body weight (kg) 68.35 ± 14.78 74.33 ± 16.03
Body height (cm) 168.57 ± 10.85 166.49 ± 10.91
BMI (kg/m2)
24.00 ± 5.70 
(n = 43)
26.83 ± 5.20
Underweight (n) 8 4
Normal weight (n) 22 3
overweight (n) 8 11
obese (n) 5 6
Body fat % – BF%
Men 
25.19 ± 0.11 
(n = 16)
33.88 ± 12.87
Women
33.00 ± 0.09 
(n = 12)
33.6 ± 9.29 
Skeletal muscle % – SM%
Men – 40.23 ± 6.65
Women – 26.60 ± 3.09
Fat mass – FM (kg)
Men
15.25 ± 9.83 
(n = 16)
30.83 ± 16.36
Women
24.07 ± 10.89 
(n = 12)
23.65 ± 9.5
NRS 2002 score 3.16 ± 1.06 –
Skeletal muscle mass 
– SMM (kg) by the 
lee et al. equation
– –
Men
28.67 ± 3.23 
(n = 19)
32.67 ± 3.53
Women
18.46 ± 4.01 
(n = 22) 
18.85 ± 3.75
Skeletal muscle mass 
index – SMI (kg/m2)
– –
Men
9.30 ± 077 
(n = 19)
10.55 ± 1.52
Women
7.11 ± 1.54 
(n = 22)
7.28 ± 1.08
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Table 2. Energy and nutrient intake based on 24-hour re-
calls and 3-day food diaries.
Data
Inpatients 
(n = 41)
Outpatients 
(n = 24)
Total energy intake (kcal/
day)
1832 2773
Energy (kcal/body weight 
kg/day)
26 39.6
carbohydrates (E%) 53.35 45.52
Sugar (E%) 15 8.75
Protein (E%) 17.47 15.24
Animal protein grams/day 52.37 57.63
Plant protein grams/day 27.19 45.46
Fat (E%) 28.6 37.29
Animal fat grams/day 39.85 65.15
Plant fat grams/day 18.38 50.88
Saturated fatty acids (SFA) 
grams/day
19.15 36.32
Monounsaturated fatty 
acids (MUFA) grams/day
18.75 36.5
Polyunsaturated fatty acids 
(PUFA) grams/day
9.5 26.6
Fibre grams/day 18 37
Fluid intake litre/day 1.5 2.15
them were moderately, whereas 8 were severely at risk 
of malnutrition. However, another 18 subjects who were 
also severe risk patients received no oNS at all. conse-
quently, it can be concluded that oNS is not provided 
based on malnutrition risk groups.
DIScUSSIoN
This study investigated the usefulness of complex 
nutritional status assessment, body composition anal-
ysis and malnutrition risk screening in case of cancer 
patients. First of all, it has been clearly seen that relying 
only on the BMI categories is not advisable since the 
high BMI values may not reveal the presence of sarcope-
nia or sarcopenic obesity. Secondly, the validated NRS 
2002 risk screening method could be used to detect the 
risk of malnutrition, however, if it is complemented by 
body composition analysis applying the previously de-
scribed BIA device, the results could be even more ac-
curate. consequently, nutrition care plans designed for 
each cancer patient individually could be set up and the 
optimal necessary nutrition process could be launched 
without delays. 
Regarding patients’ energy and nutrient intake the 
nutrition teams have to face various challenges. Not 
only the daily energy intake but the composition of pa-
tients’ diet should also be revised and altered so that 
the subjects receive all the vital macro and micronutri-
ents they need with special focus on proteins. In terms 
of fats, apart from the quantity, quality should also be 
adjusted. May oNS be not sufficient in case of the inpa-
tients, enteral and parenteral nutrition should be taken 
into consideration since this group is exposed to severe 
malnutrition and muscle wasting owing to their cachec-
tic status.
coNclUSIoNS
In summary, the results of this cross-sectional study 
demonstrate that the spectrum of cancer patients’ 
body composition is wide, ranging from the minimal or 
no weight loss and the high BMI of sarcopenic obesity 
to the extreme loss of fat and muscle. on the one hand, 
all the above mentioned altered conditions of body 
composition are associated with increased morbidity 
and mortality. on the other hand, sarcopenia and mal-
nutrition impose a remarkable burden on healthcare 
services both financially and in terms of medical care 
as well. 
Apart from malnutrition risk screening, which should 
be conducted in case of every hospital admission, it 
would also be worthwhile to examine the body com-
position and to assess the muscle mass and strength 
with the help of all currently available tools in the clini-
cal practice. Early identification of sarcopenia and mal-
nutrition would allow dietitians, working as members 
of the nutrition teams, to implement timely appropriate 
preventative and therapeutic interventions, for instance, 
by providing oNS. Following the British and American 
nutritional care plan models, continuous monitoring is 
of key importance, since patients’ needs are constantly 
changing throughout the different disease states.
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